Systemic levels of MMP9 can therefore mirror the local pathology within the bladders of IC/BPS patients, and MMP9 may prove to be a useful target for the development of novel therapeutic interventions. This evidence concerns the gene MMP9 and Bartsocas-Papas syndrome 1.